- Home
- FWONK vs PODD Comparison
FWONK vs PODD Comparison
Compare FWONK & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FWONK
- PODD
- Stock Information
- Founded
- FWONK 1950
- PODD 2000
- Country
- FWONK United States
- PODD United States
- Employees
- FWONK N/A
- PODD N/A
- Industry
- FWONK Broadcasting
- PODD Medical/Dental Instruments
- Sector
- FWONK Industrials
- PODD Health Care
- Exchange
- FWONK Nasdaq
- PODD Nasdaq
- Market Cap
- FWONK 24.9B
- PODD 22.1B
- IPO Year
- FWONK N/A
- PODD 2007
- Fundamental
- Price
- FWONK $102.57
- PODD $321.76
- Analyst Decision
- FWONK Buy
- PODD Strong Buy
- Analyst Count
- FWONK 9
- PODD 19
- Target Price
- FWONK $110.56
- PODD $346.95
- AVG Volume (30 Days)
- FWONK 1.6M
- PODD 536.4K
- Earning Date
- FWONK 11-05-2025
- PODD 11-06-2025
- Dividend Yield
- FWONK N/A
- PODD N/A
- EPS Growth
- FWONK N/A
- PODD N/A
- EPS
- FWONK 0.85
- PODD 3.45
- Revenue
- FWONK $4,033,000,000.00
- PODD $2,521,800,000.00
- Revenue This Year
- FWONK $21.87
- PODD $29.32
- Revenue Next Year
- FWONK $10.89
- PODD $18.37
- P/E Ratio
- FWONK $119.64
- PODD $93.51
- Revenue Growth
- FWONK 8.53
- PODD 27.11
- 52 Week Low
- FWONK $75.26
- PODD $230.05
- 52 Week High
- FWONK $109.36
- PODD $353.50
- Technical
- Relative Strength Index (RSI)
- FWONK 53.96
- PODD 52.32
- Support Level
- FWONK $100.22
- PODD $290.16
- Resistance Level
- FWONK $105.41
- PODD $335.00
- Average True Range (ATR)
- FWONK 3.55
- PODD 10.92
- MACD
- FWONK 0.67
- PODD 0.27
- Stochastic Oscillator
- FWONK 69.75
- PODD 71.75
About FWONK Liberty Media Corporation Series C Liberty Formula One
Liberty Media Corp along with its subsidiaries is engaged in the media and entertainment industries in North America and the United Kingdom. The company owns interests in a high-quality portfolio of assets across the media, entertainment and sports industries. The company derives its maximum revenue from United Kingdom.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.